Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
Scand J Immunol ; 100(3): e13395, 2024 Sep.
Article de Anglais | MEDLINE | ID: mdl-38973149

RÉSUMÉ

The prevalence and disease burden of chronic inflammatory diseases (CIDs) are predicted to rise. Patients are commonly treated with biological agents, but the individual treatment responses vary, warranting further research into optimizing treatment strategies. This study aimed to compare the clinical treatment responses in patients with CIDs initiating biologic therapy based on smoking status, a notorious risk factor in CIDs. In this multicentre cohort study including 233 patients with a diagnosis of Crohn's disease, ulcerative colitis, rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis or psoriasis initiating biologic therapy, we compared treatment response rates after 14 to 16 weeks and secondary outcomes between smokers and non-smokers. We evaluated the contrast between groups using logistic regression models: (i) a "crude" model, only adjusted for the CID type, and (ii) an adjusted model (including sex and age). Among the 205 patients eligible for this study, 53 (26%) were smokers. The treatment response rate among smokers (n = 23 [43%]) was lower compared to the non-smoking CID population (n = 92 [61%]), corresponding to a "crude" OR of 0.51 (95% CI: [0.26;1.01]) while adjusting for sex and age resulted in consistent findings: 0.51 [0.26;1.02]. The contrast was apparently most prominent among the 38 RA patients, with significantly lower treatment response rates for smokers in both the "crude" and adjusted models (adjusted OR 0.13, [0.02;0.81]). Despite a significant risk of residual confounding, patients with CIDs (rheumatoid arthritis in particular) should be informed that smoking probably lowers the odds of responding sufficiently to biological therapy. Registration: Clinical.Trials.gov NCT03173144.


Sujet(s)
Polyarthrite rhumatoïde , Produits biologiques , Fumer , Humains , Mâle , Femelle , Adulte d'âge moyen , Adulte , Études prospectives , Fumer/effets indésirables , Produits biologiques/usage thérapeutique , Résultat thérapeutique , Polyarthrite rhumatoïde/traitement médicamenteux , Psoriasis/traitement médicamenteux , Rectocolite hémorragique/traitement médicamenteux , Maladie chronique , Maladie de Crohn/traitement médicamenteux , Études de cohortes , Arthrite psoriasique/traitement médicamenteux , Sujet âgé , Inflammation
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE